Gilead Sciences, Inc.

Gilead Pharmasset LLC

Bristol-Myers Squibb & Gilead Sciences, Inc.

K.u. Leuven Research & Development

Other

Janssen Sciences Ireland Uc

Gerhard Puerstinger

Janssen R&d Ireland

Puerstinger, Gerhard

Reza Oliyai

Terrence C Dahl

Vahid Zia

Mark Michael Menning

Dimitrios Stefanidis

Erik Mogalian

Lauren Wiser

Choung U Kim

Valentino J Stella

Murty N Arimilli

Kenneth C Cundy

Eric Gorman

Joseph P Dougherty

Taiyin Yang

Rowchanak Pakdaman

Robert L Jerzewski

Munir A Hussain

Robert A Lipper

Adrian S Ray

Winston C Tse

David A Oare

Steven S Bondy

Hongmei Mo

Darryl G Cleary

Melissa Jean Casteel

Miriam Michelle Berrey

Charles J Reynolds

Robert G Strickley

Richard Yu

William T Symonds

Christy M Hebner

Robert G Hindes

Mark M Menning

Joanna M Koziara

Ben Chal

Brian P Kearney

Anita A Mathias

Disclosed are pharmaceutical compositions comprising Compound I, having the formula: and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.

Combination formulation of two antiviral compounds

The invention provides multilayer tablets that contain rilpivirine hydrochloride, emtricitabine, and tenofivir disoproxil fumarate. The tablets are useful for the treatment of HIV.

Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate

Disclosed are pharmaceutical compositions having an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir.

The present invention relates to therapeutic combinations of [2-(6-amino-purin-9 yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread&#xae;) and (2R,5S,cis)-4-amino-5-fluoro-1-(2 hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva&#x2122;, (&#x2212;)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.

Compositions and methods for combination antiviral therapy

Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period.

Compositions and methods for treating hepatitis C virus

In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.

Unitary pharmaceutical dosage form

The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread&#xae;) and (2R,5S,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva&#x2122;, (&#x2212;)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.

In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, componentcomprising tenofovir DF (and, optionally, emtricitabine) and componentcomprising efavirenz, wherein componentsandare in a stabilizing configuration. In preferred embodiments componentis made by dry granulation.

This invention is directed to a composition comprising dry granulated tenofovir DF and emtricitabine, and a method for making same. Dry granulation was unexpectedly found to be important in preparing a tenofovir DF containing composition suitable for inclusion in a combination dosage form containing emtricitabine, efavirenz and tenofovir DF.

Method and composition for pharmaceutical product

Growing community of inventors

Burlingame, CA, United States of America

Reza Oliyai